Scottish biotech Mironid is in the preclinical stages of developing a treatment for autosomal dominant polycystic kidney disease, a genetic condition which for around half of patients can led to kidney failure by the time they reach 60 years of age. In Vivo spoke to chief medical officer Cass Kelleher about the company’s development strategy.
For patients with autosomal dominant polycystic kidney disease (ADKPD), abnormalities in two different genes – PKD1, which accounts for around 78% of cases, and PKD2, which accounts for around 15% – disrupt the regular development of the kidneys and cause cysts to grow, due to abnormally elevated levels of cyclic adenosine monophosphate (cAMP) enzymes.
A person has a 50% chance of developing the condition if one of their parents has one of the faulty...
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
The seventh annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
The seventh annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.
